We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PetMed (PETS) Tops Q2 Earnings & Sales Estimates, Margins Up
Read MoreHide Full Article
PetMed Express, Inc. (PETS - Free Report) announced earnings per share (EPS) of 43 cents for the second quarter of fiscal 2018, up 79.2% from the year-ago quarter’s 24 cents. Also, earnings surpassed the Zacks Consensus Estimate by 43.3%.
The year-over-year rise in earnings was driven by an increase in sales and improved margins.
Net sales in the reported quarter rose 10% year over year to $66.7 million, outpacing the Zacks Consensus Estimate by 5.9%.
PetMed Express, Inc. Price, Consensus and EPS Surprise
Per this leading pet pharmacy in Americas, the upside in sales was a result of increased new orders and reorders during the quarter.
In the reported quarter, reorder sales increased 9.9% to $55.1 million on a year-over-year basis, while new order sales rose 8.8% to $11.6 million.
Average order value was approximately $85 in the quarter compared with $82 in the year-ago quarter. We note that the variation in average order value is mainly driven by a shift of sales to higher priced items.
Per the company, the seasonality in its business is mainly because of the proportion of flea, tick and heartworm medications in the product mix. Spring and summer are considered peak seasons while fall and winter represent off-seasons.
During the quarter under review, PetMed acquired 134,000 new customers, up from 131,000 a year ago. Roughly, 84% of all orders was generated from its website (versus 82% in the prior-year quarter).
Gross margin expanded 548 basis points (bps) year over year to 35.2% in the reported quarter. General and administrative expenses were up 7.5% year over year to $6.2 million. Also, advertising expenses rose 3.3% to $4.5 million. This led to a 5.6% increase in adjusted operating expenses (without depreciation expense), which amounted to $10.7 million. Nevertheless, adjusted operating margin in the quarter rose 610 bps to 19.1% from the year-ago quarter.
PetMed exited the fiscal second quarter with cash and cash equivalents of $68.4 million compared with $68.5 million at the end of the first-quarter fiscal 2017. The company also announced a quarterly dividend of 20 cents per share, payable to shareholders of record as of Nov 17, 2017.
Our Take
PetMed successfully delivered yet another quarter of solid results. In the fiscal second quarter, the company once again topped the Zacks Consensus Estimate on both revenues and earnings. We are also encouraged to note the stellar increase in reorder and new order sales in the quarter.
The company is also striving to implement several strategies to revitalize its top line. These include increased focus on advertising efficiency to boost new order sales and shifting sales to higher margin items, while also expanding product offerings.
PetMed currently offers a wide range of products catering to dogs, cats and horses besides working on upgrading its existing portfolio.
Abbott has a long-term expected earnings growth rate of 10.7%. The stock rallied roughly 39.5% over the last year.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock surged 48.2% last year.
Thermo Fisher has a long-term expected earnings growth rate of 11.7%. The stock gained 31.4% last year.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
PetMed (PETS) Tops Q2 Earnings & Sales Estimates, Margins Up
PetMed Express, Inc. (PETS - Free Report) announced earnings per share (EPS) of 43 cents for the second quarter of fiscal 2018, up 79.2% from the year-ago quarter’s 24 cents. Also, earnings surpassed the Zacks Consensus Estimate by 43.3%.
The year-over-year rise in earnings was driven by an increase in sales and improved margins.
Net sales in the reported quarter rose 10% year over year to $66.7 million, outpacing the Zacks Consensus Estimate by 5.9%.
PetMed Express, Inc. Price, Consensus and EPS Surprise
PetMed Express, Inc. Price, Consensus and EPS Surprise | PetMed Express, Inc. Quote
Per this leading pet pharmacy in Americas, the upside in sales was a result of increased new orders and reorders during the quarter.
In the reported quarter, reorder sales increased 9.9% to $55.1 million on a year-over-year basis, while new order sales rose 8.8% to $11.6 million.
Average order value was approximately $85 in the quarter compared with $82 in the year-ago quarter. We note that the variation in average order value is mainly driven by a shift of sales to higher priced items.
Per the company, the seasonality in its business is mainly because of the proportion of flea, tick and heartworm medications in the product mix. Spring and summer are considered peak seasons while fall and winter represent off-seasons.
During the quarter under review, PetMed acquired 134,000 new customers, up from 131,000 a year ago. Roughly, 84% of all orders was generated from its website (versus 82% in the prior-year quarter).
Gross margin expanded 548 basis points (bps) year over year to 35.2% in the reported quarter. General and administrative expenses were up 7.5% year over year to $6.2 million. Also, advertising expenses rose 3.3% to $4.5 million. This led to a 5.6% increase in adjusted operating expenses (without depreciation expense), which amounted to $10.7 million. Nevertheless, adjusted operating margin in the quarter rose 610 bps to 19.1% from the year-ago quarter.
PetMed exited the fiscal second quarter with cash and cash equivalents of $68.4 million compared with $68.5 million at the end of the first-quarter fiscal 2017. The company also announced a quarterly dividend of 20 cents per share, payable to shareholders of record as of Nov 17, 2017.
Our Take
PetMed successfully delivered yet another quarter of solid results. In the fiscal second quarter, the company once again topped the Zacks Consensus Estimate on both revenues and earnings. We are also encouraged to note the stellar increase in reorder and new order sales in the quarter.
The company is also striving to implement several strategies to revitalize its top line. These include increased focus on advertising efficiency to boost new order sales and shifting sales to higher margin items, while also expanding product offerings.
PetMed currently offers a wide range of products catering to dogs, cats and horses besides working on upgrading its existing portfolio.
Zacks Rank & Key Picks
PetMed currently has a Zacks Rank #3(Hold). A few better-ranked stocks in the medical sector are Abbott (ABT - Free Report) , IDEXX Laboratories, Inc. (IDXX - Free Report) and Thermo Fisher Scientific Inc. (TMO - Free Report) , all three carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Abbott has a long-term expected earnings growth rate of 10.7%. The stock rallied roughly 39.5% over the last year.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock surged 48.2% last year.
Thermo Fisher has a long-term expected earnings growth rate of 11.7%. The stock gained 31.4% last year.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>